Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Relevance of Modifying RANKL Signaling During Folliculogenesis

NCT07546552 is registered in ClinicalTrials.gov with Peter Humaidan as lead sponsor.

NCT NCT07546552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07546552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Relevance of Modifying RANKL Signaling During Folliculogenesis
Lead sponsor
Peter Humaidan
Phase
Not applicable
Overall status
Recruiting
Start date
August 1, 2025
Completion date
March 15, 2028
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

female infertility, follicle development, nf-κb ligand, osteoporosis, rankl